The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1--deficient ovarian tumors and can be exploited to improve treatment response in a mouse model.

Gina Mantia-Smaldone,Lukas Ronner,Anne Blair,Victoria Gamerman,Christopher Morse,Sandra Orsulic,Stephen Rubin,Phyllis Gimotty,Sarah Adams

Gynecologic Oncology（2014）

引用 16|浏览5

暂无评分

摘要

•BRCA1 dysfunction alters the immunophenotype of ovarian cancer cells.•BRCA1− tumors are susceptible to immunomodulation by PLD.•BRCA1 ovarian cancer patients are candidates for PLD combined with immunotherapy.

查看译文

关键词

BRCA,Ovarian cancer,Pegylated Liposomal Doxorubicin,Immunomodulation,Host immunity,T cells

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要